An dieser Stelle entsteht die Studiensammlung mit den Studien und Veröffentlichungen, auf die auf den einzelnen Seiten hingewiesen wird.

Alzheimer Grundlagen

Bondi MW, Edmonds EC, Salmon DP, Alzheimer’s Disease: Past, Present and Future. J I Neuropsychol Soc, Oct 2017, 23 (9-10): 818-831

Fotuhi, M., Do, D. and Jack, C. (2012) ‘Modifiable factors that alter the size of the hippocampus with ageing’, Nature Reviews Neurology. Nature Publishing Group, 8(4), pp. 189–202. doi: 10.1038/nrneurol.2012.27.

Hane, F. T. et al. (2017) ‘Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment’, Journal of Alzheimer’s Disease, 57(3), pp. 645–665. doi: 10.3233/JAD-160907.

Preische, O. et al. (2019) ‘Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease’, Nature Medicine, 25(2), pp. 277–283. doi: 10.1038/s41591-018-0304-3.

Reitz, C. (2015) ‘Genetic diagnosis and prognosis of Alzheimer’s disease: Challenges and opportunities’, Expert Review of Molecular Diagnostics, 15(3), pp. 339–348. doi: 10.1586/14737159.2015.1002469.

Robinson, M., Lee, B. Y. and Hane, F. T. (2017) ‘Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology’, Journal of Alzheimer’s disease : JAD, 57(2), pp. 317–330. doi: 10.3233/JAD-161149.

Ropper AH, Samuels MA, Klein JP; Adams & Victor’s Principles of Neurology 10thedition, 2014

van der Flier, W. M. and Scheltens, P. (2005) ‘Epidemiology and risk factors of dementia’, Journal of Neurology, Neurosurgery & Psychiatry, 76(suppl 5), p. v2 LP-v7. doi: 10.1136/jnnp.2005.082867.

Weston, P. S. J. et al. (2017) ‘Serum neurofilament light in familial Alzheimer disease’, Neurology, 89(21), pp. 2167–2175. doi: 10.1212/WNL.0000000000004667.


Briggs R, Kennely SP, O’Nail D; Drug treatment in Alzheimer’s disease. Clinical Medicine 2016

Hane FT, Robinson M et al; Recent Progress in Alzheimer’s disease research, part 3: diagnosis and treatment.J Alzheimers Dis 2017

Hogan DB; Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer’s disease. Can J Psychiatry 2014

May PC, Dean RA, Lowe SL et al; Robust central reduction of amyloid-ß in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 2011.

McAree, M. et al., 2019. Osteopathic Cranial Manipulative Medicine and the Blood-Brain Barrier: A Mechanistic Approach to Alzheimer Prevention. The Journal of the American Osteopathic Association, 13 5.

McShane R, Westby MJ, Roberts E et al; Memantine for dementia. Cochrane Database Syst Rev 2019

Rabins PV, Rovner BW, Rummans T et al; Guideline Watch (October 2014): Practice Guideline For The Treatment Of Patients With Alzheimer’s Disease And Other Dementias. org.

Raina P, Santaguida P, Ismalia A et al; Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008.

Shahpasand K, Shamloo AS, et al; “Tau immunotherapy: Hopes and hindrances”.Hum Vaccin Immunother 2018.

Vassar R;BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther 2014


Liu X, Du X, Han G, Gao W. Association between tea consumption and risk of cognitive disorders: A dose-response meta-analysis of observational studies. Oncotarget. 2017;8(26):43306-43321. doi:10.18632/oncotarget.17429

Raji, C. A. et al. (2014) ‘Regular Fish Consumption and Age-Related Brain Gray Matter Loss’, American Journal of Preventive Medicine, 47(4), pp. 444–451. doi: 10.1016/j.amepre.2014.05.037.


Berr C, Balansard B, Arnaud J, Roussel AM, Alpérovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA Study. Etude du Vieillissement Artériel. J Am Geriatr Soc. 2000;48(10):1285–1291.

Cardoso BR, Cominetti C, Cozzolino SM. Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease. Clin Interv Aging. 2013;8:531-42.

Cardoso BR, Ong TP, Jacob-Filho W, Jaluul O, Freitas MI, Cozzolino SM. Nutritional status of selenium in Alzheimer’s disease patients. Br J Nutr. 2010;103(6):803–806.

Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33-44

Gröber, Uwe: Orthomolekulare Medizin. Ein Leitfaden für Apotheker und Ärzte. Wissenschaftliche Verlagsgesellschaft, Stuttgart: 2008

Koeberle, Andreas; Northoff, Hinnak; Werz, Oliver (2009): Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. In: Molecular cancer therapeutics 8 (8), S. 2348–2355. DOI: 10.1158/1535-7163.MCT-09-0290.

Oulhaj A, Jernerén F, Refsum H, Smith AD, de Jager CA. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. J Alzheimers Dis. 2016;50(2):547-57.

Omar SH. Oleuropein in olive and its pharmacological effects. Sci Pharm. 2010;78(2):133-54

Parudariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2010;469(1):6–10.

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer’s Disease, N Engl J Med 1997; 336:1216-1222

Siri-Tarino, Patty W.; Sun, Qi; Hu, Frank B.; Krauss, Ronald M. (2010): Saturated Fatty Acids and Risk of Coronary Heart Disease: Modulation by Replacement Nutrients. In: Curr Atheroscler Rep 12 (6), S. 384–390. DOI: 10.1007/s11883-010-0131-6.

Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.

Seshadri S, Beiser A, Selhub J, Jacques PF et al, Plasmahomocysteine as a risk factor for dementia and Alzheimer’s disease, N Engl J Med 2002; 346:476-483

Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis. 2014;38(1):111-20.

Talahalli, Ramaprasad R.; Vallikannan, Baskaran; Sambaiah, Kari; Lokesh, Belur R. (2010): Lower efficacy in the utilization of dietary ALA as compared to preformed EPA + DHA on long chain n-3 PUFA levels in rats. In: Lipids 45 (9), S. 799–808. DOI: 10.1007/s11745-010-3464-6.

Thomson CD, Chisholm A, McLachlan SK, Campbell JM. Brazil nuts: an effective way to improve selenium status. Am J Clin Nutr. 2008; 87(2):379–384.

Wu, Jason H Y; Hodgson, Jonathan M.; Clarke, Michael W.; Indrawan, Adeline P.; Barden, Anne E.; Puddey, Ian B.; Croft, Kevin D. (2009): Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies. In: Hypertension 54 (5), S. 1151–1158. DOI: 10.1161/HYPERTENSIONAHA.109.139352.

Schadeinflüsse und Toxine

Xu, L. et al. (2018) ‘Circulatory Levels of Toxic Metals (Aluminum, Cadmium, Mercury, Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review’, Journal of Alzheimer’s Disease, 62(1), pp. 361–372. doi: 10.3233/JAD-170811.

Sport und Bewegung

Varma, V. R. et al. (2015) ‘Low-intensity daily walking activity is associated with hippocampal volume in older adults’, Hippocampus, 25(5), pp. 605–615. doi: 10.1002/hipo.22397.

Raji, C. A., Merrill, D. A., Eyre, H., Mallam, S., Torosyan, N., Erickson, K. I., Lopez, O. L., Becker, J. T., Carmichael, O. T., Gach, H. M., Thompson, P. M., Longstreth, W. T., Kuller, L. H., 2016. Longitudinal relationships between caloric expenditure and gray matter in the cardiovascular health study. Journal of Alzheimer’s disease : JAD 52 (2), 719-729.

Diese Seite wird kontinuierlich erweitert

Unterstützen Sie das Projekt über betterplace,

dann geht es schneller…


Unterstützen Sie uns jetzt!